Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR)

Virtu Financial LLC acquired a new stake in shares of Vor Biopharma Inc. (NYSE:VOR) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 54,470 shares of the company’s stock, valued at approximately $60,000. Virtu Financial LLC owned 0.08% of Vor Biopharma at the end of the most recent reporting period.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on VOR shares. JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Vor Biopharma in a report on Thursday, March 20th. HC Wainwright cut their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a report on Friday, March 21st. Stifel Nicolaus cut their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Oppenheimer reiterated an “outperform” rating and issued a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma presently has a consensus rating of “Buy” and a consensus target price of $8.86.

Vor Biopharma Stock Down 4.4 %

Shares of NYSE:VOR opened at $0.72 on Tuesday. The firm has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.00. Vor Biopharma Inc. has a 52 week low of $0.63 and a 52 week high of $2.43. The stock has a market capitalization of $89.89 million, a P/E ratio of -0.44 and a beta of -0.40.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.